(prostaglandin D2 receptor 1) (Sturino et al, in press ) that is undergoing preclinical and clinical development for the treatment of niacin-induced flushing. Niacin (nicotinic acid), a member of the vitamin B complex, has been used as a dietary supplement in milligram quantities and as a successful plasma lipid-modifying agent when administered in gram quantities. Niacin decreases plasma concentrations of cholesterol, free fatty acids and triglycerides in humans, raises plasma HDL cholesterol (Shepherd et al, 1979) and lowers plasma VLDL and LDL cholesterol (Knopp et al, 1999) . Furthermore, studies have
shown that niacin can be effectively combined with statins to treat patients with low HDL cholesterol (Zhao et al, 2004 , Rubenfire et al, 2004 . The major side-effect with niacin therapy is the mild to severe cutaneous flushing experienced by patients that is mediated by vasodilation (Vogt et al, 2006) . MK-0524, a potent DP1 antagonist has an IC 50 value of 1.1 nM in a mouse DP1 functional assay (unpublished results) and has been shown to block niacin-induced vasodilation in the mouse by ~80% (Cheng et al, 2006) .
Furthermore, clinical studies have demonstrated the efficacy of MK-0524 in attenuating niacin-induced vasodilation/flushing (Cheng et al, 2006) .
The objective of the present study is to investigate the absorption, metabolism and excretion of [
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min. Plasma was separated and stored as two aliquots at -20°C for qualitative and quantitative analysis. Urine samples voided predose and at specific intervals (0-6, 6-12, 12-24, 24-48, 48-72, 72-96 and 96-120 hr) were stored at -20°C. All fecal samples and wipes were individually packaged during pre-dose and throughout the 7 days post-dose.
Exhaled CO 2 was collected pre-dose (within 2 hr of dosing) and at 1 and 4 hr post-dose.
Subjects were instructed to exhale through a one-way valve into scintillation vials containing 4 mL of 1:1 mixture of 1 M hyamine hydroxide solution and ethanol and trace amounts of 1% thymophtalein (blue indicator). The blue solution turns clear upon CO 2 collection in approximately 40 to 60 sec. Following collection, Scintisafe Gel cocktail (12 mL) was added to each sample; the samples were then stored in darkness at 4°C.
Sample Preparation. Plasma. Samples were stored at -20C before extraction for analysis. Previously studies were conducted to demonstrate that the acyl glucuronide metabolite (M2) underwent minimum hydrolysis (0.1%) when plasma samples were stored on ice for up to 6 hr (Schwartz et al, 2006) . Human plasma was prepared for HPLC-MS/MS analysis by the addition of nine volumes of acetonitrile containing a stable isotope labeled internal standard. After mixing and centrifugation, the supernatant was acidified (using an equal volume of dilute formic acid in 40% acetonitrile) to prevent hydrolysis of an acyl glucuronide metabolite found in post dose plasma samples. The sample preparation procedure utilized 96-well plates and was partly automated using a robotic sample processor.
For metabolite profiling, an equal volume (1 mL) of plasma samples collected at 1, 2, 4, and 12 hr from each individual was pooled and mixed with 3 mL acetonitrile:water (2:1). The samples were sonicated for 10 min, vortex mixed for 10 min, and centrifuged This article has not been copyedited and formatted. The final version may differ from this version. at 3000 rpm for 10 min. The supernatant was removed and the pellets were resuspended in 3 mL acetonitrile:water (2:1) by sonicating for 30 min and vortex mixing for 10 min.
The samples were then centrifuged at 3000 rpm for 10 min and the supernatants evaporated to dryness under N 2 .
The dried extracts were reconstituted with water:acetonitrile:50% acetic acid (7:2:1, v/v/v).
Urine. For metabolite profiling, 0 to 120 hr pools of urine samples were prepared for each subject based on volume, wherein a fixed fraction of the total volume of urine from each interval was pooled. Aliquots (5 mL) from each of these pools were combined.
Approximately 100,000 dpm (10 mL) was removed from the urine pool and dried under N 2 at 25 o C overnight. The residue was reconstituted with water: acetonitrile: 50% acetic acid (7:2:1, v/v/v), sonicated for 10 min, centrifuged at 3000 rpm for 10 min, then analyzed by LC-MS with radiometric detection. A representative metabolite profile was generated by analyzing a sample consisting of equal volumes of urine extracts from the 6 subjects.
For isolation of the urea adducts from urine, 5 to 10 ml of urine was evaporated under N2
and the residue reconstituted with water: acetonitrile: 50% acetic acid (7:2:1, v/v/v), sonicated for 10 min, centrifuged at 3000 rpm for 10 min. The extracts were analyzed by RP-HPLC and the radioactive peaks corresponding to each of the adducts were separately collected. Following evaporation of the solvent under a stream of nitrogen, the samples were reanalyzed using a new column and the pooled fractions were concentrated and subjected to HPLC and NMR analysis. for the detection of parent compound and internal standard, respectively. The standard curve range was 10 to 2500 ng/mL. Pharmacokinetics. The apparent terminal rate constant (λ) for both radioactivity and MK-0524 plasma concentrations was estimated by regression of the terminal log-linear portion of the concentration-time profile (using quantifiable concentrations only); t ½ was calculated as the quotient of ln (2) Figure 2 . Individual plasma MK-0524 and radioactivity pharmacokinetic parameters are listed in Table 2 . MK-0524 accounted for approximately 29% of the radioactivity in plasma, as determined by the AUC ratio of MK-0524 to radioactivity.
Measurement of Radioactivity
Following oral administration, [14C]MK-0524 was absorbed rapidly; the highest MK-0524 as well as total radioactivity concentrations in plasma (C max ) were achieved, on average, between 1 to 1.5 hr and ranged from 1.27 to 3.59 µM eq (mean value 2.34 µM eq) and 3.60 and 6.44 µM (mean value 5.07 µM), respectively. Figure 1 shows the structures of metabolites Phase II (glucuronide conjugate) metabolites.
Identification of Metabolites

Metabolite Profiles in Feces
The metabolite profile of a pooled human fecal sample collected at 0 to 168 hr is presented in Figure 7 . Parent compound was the major radioactive component in feces, comprising 73% of the radioactivity. Also present in the feces were the two hydroxylated metabolites, M1 and M4, which comprised 10% of the radioactivity, and the keto derivative, M3, which comprised 17% of the total radioactivity. The radioactivity in feces was thus comprised of 73% parent compound and 27% Phase I (oxidative) metabolites.
This article has not been copyedited and formatted. The final version may differ from this version. of the administered dose was recovered in feces during a 7-day period. Urinary excretion averaged 22% of the administered dose, during a 5-day period. The total mean recovery of radioactivity was ~90%. The excretion pattern was similar in all six subjects.
Absorption was rapid with peak plasma concentrations of total radioactivity and parent compound being achieved within 1. The stability of M2 in plasma was studied previously (Chang et al, in press ). Briefly, when incubated with fresh plasma from rat, dog and human, M2 underwent acyl migration to form transient isomeric products and finally hydrolyzed to form the parent compound. The in vitro half-life for M2 hydrolysis in plasma ranged from 1 to 3 hr in This article has not been copyedited and formatted. The final version may differ from this version. these species. In this study, human plasma collection methods were optimized and validated to prevent hydrolysis of M2. Studies were conducted to demonstrate that the relative extent of hydrolysis of M2 was ~0.1% when plasma samples were stored on ice for 6 hr (Schwartz et al, 2006) . Glucuronidation has been considered as the most common phase II reaction and is mainly a mechanism of detoxification and elimination for a wide variety of endogenous substrates and xenobiotics in mammals. Acyl glucuronides are usually susceptible to hydrolysis by beta glucuronidases present in the gut, non-specific esterases, serum albumin and hydroxide ion (Bailey and Dickinson, 2003, Koster et al., 1985) .
Following oral administration of MK-0524, about 22% of the administered radioactive dose was excreted in the urine. The major component in urine samples was M2, the acyl glucuronide, comprising ~64% of the total radioactivity, along with urea adducts of the hydroxylated epimers (M1/M4) and of their corresponding glucuronides.
In addition, M3 (the keto metabolite) was a minor component in human urine. Detailed in vitro studies conducted following incubation of M1 and M4 in the presence of urea and/or control human urine, indicated that these urea adducts could have formed in vitro during the storage of study samples and appear to be chemical artifacts arising from M1/M4. Standards of M1 and M4 were found to readily epimerize when analyzed with LC-MS and formed urea adducts when allowed to stand in blank urine or 2.5 M urea.
Based on these observations, a plausible mechanism for the formation of the urea adducts involves the acid-catalyzed elimination of water to form a resonance-stabilized carbocation. This carbocation can be trapped by urea to form both urea adduct epimers or water to regenerate the epimers M1/M4. Thus, the routes of elimination of MK-0524 in humans appear to be similar to those in preclinical species. In rats and dogs MK-0524 was cleared via metabolism exclusively by way of glucuronidation, followed by excretion of the acyl glucuronide (M2) into bile, which represented >95% of the total radioactivity (Chang et al, in press ). This article has not been copyedited and formatted. The final version may differ from this version.
